Safety and Efficacy Study of Isolagen TherapyTM in Treatment of Facial Wrinkles and Creases | NCT00654654 | Trialant
CompletedInterventionalPhase 2Updated Mar 13, 2012
Safety and Efficacy Study of Isolagen TherapyTM in Treatment of Facial Wrinkles and Creases
ClinicalTrials.gov ID
NCT00654654
Lead Sponsor
Castle Creek Biosciences, LLC.INDUSTRY
Overall Status
Completed
Study Type
Interventional
Phase
Phase 2
Enrollment
50Actual
Last Update Posted
Mar 13, 2012Estimated
Start Date
Mar 2007
Primary Completion Date
Jun 2008Actual
Completion Date
Jun 2008Actual
Brief Summary
The purpose of this study is to evaluate the safety profile and the treatment effect of autologous human fibroblasts and placebo when administered to facial wrinkles and creases
Facial Wrinkles and Creases
Autologous Human Fibroblasts (azficel-T)
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male or female, at least 18 years of age
High Investigator wrinkle severity assessment score
Subject assessment of dissatisfaction of facial appearance
Provide written informed consent and comply with the study requirements